Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Albendazole showed no clear difference in seizure recurrence ‐ all participants compared with placebo or no anthelmintics (low certainty).
Albendazole probably leads to lower seizure recurrence ‐ participants with a single cyst compared with placebo or no anthelmintics (moderate certainty).
It is very uncertain whether albendazole changes seizure recurrence ‐ participants with multiple (> 1) cysts compared with placebo or no anthelmintics (very low certainty).
Albendazole probably leads to higher complete radiological clearance of lesions compared with placebo or no anthelmintics (moderate certainty).
Albendazole probably leads to higher evolution of cysts compared with placebo or no anthelmintics (moderate certainty).
Zinc supplementation showed no clear difference in preterm birth (< 37 weeks) compared with no zinc (with or without placebo) (low certainty).
Zinc supplementation showed no clear difference in stillbirth compared with no zinc (with or without placebo) (low certainty).
It is very uncertain whether zinc supplementation changes neonatal death compared with no zinc (with or without placebo) (very low certainty).
Zinc supplementation showed no clear difference in perinatal death compared with no zinc (with or without placebo) (low certainty).
Zinc supplementation showed no clear difference in small‐for‐gestational age or IUGR compared with no zinc (with or without placebo) (moderate certainty).
Zinc supplementation showed no clear difference in low Birthweight (< 2500 g) compared with no zinc (with or without placebo) (moderate certainty).
Dornase alfa leads to higher relative mean percentage change in FVC (% predicted) at 6 months compared with placebo or no dornase alfa treatment (high certainty).
Dornase alfa showed no clear difference in change in quality of life ‐ CFQ‐R respiratory at 1 month compared with placebo or no dornase alfa treatment (low certainty).
Dornase alfa probably leads to lower number of people experiencing exacerbations at up to 2 years compared with placebo or no dornase alfa treatment (moderate certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).